Ibandronic Acid

Ibandronic Acid

SCHEMBL1240197

CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O.O.O.[NaH].[NaH]

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

FDPS

The experimentally established mechanism targets of Ibandronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
FDPS known ✓ P14324 19/20 0.93
GGPS1 O95749 8/20 0.93
AGTR1 P30556 1/20 0.93
OPRM1 P35372 1/20 0.93
PDE3A Q14432 1/20 0.93
S1PR2 O95136 1/20 0.57
S1PR1 P21453 1/20 0.57
S1PR3 Q99500 1/20 0.57
S1PR5 Q9H228 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ibandronic Acid SCHEMBL28564280 1.00 FDPS (0.93) FDPSGGPS1AGTR1OPRM1PDE3A
Ibandronic Acid SCHEMBL3415425 1.00 FDPS (0.93) FDPSGGPS1AGTR1OPRM1PDE3A
Ibandronic Acid SCHEMBL365290 1.00 FDPS (0.93) FDPSGGPS1AGTR1OPRM1PDE3A
Ibandronic Acid SCHEMBL3624745 0.98 FDPS (0.90) FDPSGGPS1AGTR1OPRM1PDE3A
Ibandronic Acid SCHEMBL163394 0.98 FDPS (0.90) FDPSGGPS1AGTR1OPRM1PDE3A
Ibandronic Acid SCHEMBL3630021 0.98 FDPS (0.90) FDPSGGPS1AGTR1OPRM1PDE3A
Ibandronic Acid SCHEMBL3628878 0.98 FDPS (0.90) FDPSGGPS1AGTR1OPRM1PDE3A
Ibandronic Acid SCHEMBL3419518 0.98 FDPS (0.97) FDPSGGPS1AGTR1OPRM1PDE3A
Ibandronic Acid SCHEMBL1579193 0.98 FDPS (0.97) FDPSGGPS1AGTR1OPRM1PDE3A
Ibandronic Acid SCHEMBL1030766 0.98 FDPS (0.97) FDPSGGPS1AGTR1OPRM1PDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3513782-A1 GEL FORMULATIONS FOR ORAL ADMINISTRATION OF DRUGS, IN PARTICULAR TO DYSPHAGIC PATIENTS Universita' Degli Studi Di Camerino (IT) 2019-07-24 EP claimed
CN-103554177-B A kind of method preparing sodium Ibandronate monohydrate 安徽省先锋制药有限公司 2016-06-29 CN claimed
US-9044401-B2 Composition for preventing or treating osteoporosis, and manufacturing method therefor NAVIPHARM CO., LTD. (KR) 2015-06-02 US claimed
CN-104277070-A Preparation method of sodium ibandronate monohydrate HUBEI WATERSTONE BIO PHARMACEUTICAL TECHNOLOGY CO LTD 2015-01-14 CN claimed
US-20130096091-A1 COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS, AND MANUFACTURING METHOD THEREFOR DREAM PHARMA CORPORATION (KR) 2013-04-18 US claimed
WO-2021161987-A1 BISPHOSPHONATE-CONTAINING CARBON PARTICLE COMPOSITE AND METHOD FOR PRODUCING SAME 国立研究開発法人産業技術総合研究所 2021-08-19 WO disclosed
EP-3513782-A1 GEL FORMULATIONS FOR ORAL ADMINISTRATION OF DRUGS, IN PARTICULAR TO DYSPHAGIC PATIENTS Universita' Degli Studi Di Camerino (IT) 2019-07-24 EP disclosed
CN-106511356-B A kind of ibandronic acid composition of sodium and preparation method thereof 南京恒生制药有限公司 2019-02-26 CN disclosed
CN-109293695-A Bis- phosphonopropyl of N-(3- hydroxyl -3,3-)-N- methylpentane -1- amine oxide and the like and purposes 天津红日药业股份有限公司 2019-02-01 CN disclosed
CN-104922060-B A kind of Ibandronate composition 河北仁合益康药业有限公司 2017-10-20 CN disclosed
CN-106511356-A Sodium ibandronate composition and preparation method thereof 南京恒生制药有限公司 2017-03-22 CN disclosed
CN-103554177-B A kind of method preparing sodium Ibandronate monohydrate 安徽省先锋制药有限公司 2016-06-29 CN disclosed
WO-2013109198-A1 PROCESSES FOR THE PREPARATION OF SODIUM IBANDRONATE MONOHYDRATE POLYMORPHS A, B AND MIXTURE OF POLYMORPHS A WITH B KOÇAK FARMA İLAÇ VE KİMYA SANAYİ ANONİM ŞİRKETİ (TR) 2013-07-25 WO disclosed
US-20130096091-A1 COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS, AND MANUFACTURING METHOD THEREFOR DREAM PHARMA CORPORATION (KR) 2013-04-18 US disclosed
EP-2581086-A2 COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS, AND MANUFACTURING METHOD THEREFOR Navipharm Co, Ltd (KR) 2013-04-17 EP disclosed
EP-2470549-A1 PROCESS FOR MAKING 1-HYDROXYALKYLIDENE-1,1-BIPHOSPHONIC ACIDS Synthon B.V. (NL) 2012-07-04 EP disclosed
WO-2011023280-A1 PROCESS FOR MAKING 1-HYDROXYALKYLIDENE-1,1-BIPHOSPHONIC ACIDS SYNTHON B.V. (NL) 2011-03-03 WO disclosed
WO-2011016738-A1 A PROCESS FOR THE SYNTHESIS OF 1-HYDROXY-3-(N-METHYLPENTYLAMINO) PROPYLIDENE BISPHOSPHONIC ACID MONOSODIUM SALT, MONOHYDRATE ZAKLADY FARMACEUTYCZNE POLPHARMA SA (PL) 2011-02-10 WO disclosed
WO-2008058722-A1 REAGENT AND USE THEREOF FOR THE PRODUCTION OF BISPHOSPHONATES SANDOZ A/S (DK) 2008-05-22 WO disclosed
EP-1923394-A1 Reagent and use thereof for the production of bisphosphonates Sandoz A/S (DK) 2008-05-21 EP disclosed